Tiotropium in Patients with Bronchiectasis: A Prospective Cohort Study

• Published in: Lung Vol. 201; no. 1; pp. 9 - 15
• Main Authors: Shi, Zu-Liang, Zhang, Hong-Ying, Peng, Hai-Bo, Zhu, Zhong-Ming
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2023; Springer; Springer Nature B.V
• Subjects: Air flow; Analysis; Bronchiectasis; Bronchodilator Agents - therapeutic use; Bronchodilators; Care and treatment; Cohort analysis; Humans; Lung diseases; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Patients; Pneumology/Respiratory System; Prospective Studies; Pulmonary Disease, Chronic Obstructive - drug therapy; Risk reduction; Scopolamine Derivatives - therapeutic use; Tiotropium; Tiotropium Bromide - therapeutic use; Treatment Outcome; Bronchodilators; Tiotropium; Bronchiectasis; Cohort study
• ISSN: 0341-2040; 1432-1750
• DOI: 10.1007/s00408-023-00597-8

Purpose There are limited studies on the use of bronchodilators for the treatment of bronchiectasis. This study investigated the efficacy of tiotropium in patients with bronchiectasis and airflow limitation. Methods This study was a prospective cohort study, including 169 patients with bronchiectasis and airflow limitation from 2015 to 2019. The clinical outcomes observed in our study were the effect of tiotropium on the frequency of moderate exacerbations, the time to the first severe exacerbation, and the annual decline in FEV 1 . Results After 12 months, the annual decline in the FEV 1 after bronchodilator use was 27.08 ml or 42.9 ml per year in the group with or without tiotropium, respectively. Treatment with tiotropium was associated with a decreased risk of moderate exacerbation of bronchiectasis (Adjusted RR 0.618 95% CI 0.493–0.774; P  < 0.005). The time to the first severe acute exacerbation of bronchiectasis in the tiotropium group was longer than the non-tiotropium group (Adjusted HR 0.333 95% CI 0.219–0.506; P  < 0.001). Conclusion In conclusion, prospective cohort study showed that tiotropium effectively ameliorated the annual decline in the FEV 1, with a lower-risk rate of moderate exacerbations and prolonging the time to the first-time severe exacerbation in patients with bronchiectasis and airflow limitation.